Summary
Charcot-Marie-Tooth disease is genetically heterogeneous, with more than 100 genes associated with different CMT disease subtypes.
Currently, no approved therapies are available for the treatment of CMT disease, leaving patients with limited treatment options. As a result, there remains a significant unmet need for effective therapies that can modify disease progression rather than simply manage symptoms.
Some of the CMT disease drugs under development include IFB-088 (InFlectis BioSciences), Govorestat (Applied Therapeutics), Ignaseclant (NMD670) (NMD Pharma), ABS-0871 (Actio Biosciences), VCA-894A (Vanda Pharmaceuticals), EDK060 (Novartis), AGT-100...
